Physician profile
Mark M Malkus
NPI 1033286703
$1,183.28
in general payments reported to CMS, 2019-2025
20 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.34 · 2020: $61.91 · 2021: $103 · 2022: $187 · 2023: $108 · 2024: $424 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $737.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $245.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $207.64 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $181.41 | 2023-2025 | |
| Pfizer INC. | $154.59 | 2019-2025 | |
| Astellas Pharma US INC | $51.26 | 2024-2025 | Veozah |
| Watermark Medical, INC. | $35.44 | 2024 | |
| Abbott Laboratories | $33.34 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.32 | 2019-2023 | Tradjenta, Jardiance |
| Corcept Therapeutics | $32.85 | 2022-2024 | Korlym |
| Glaxosmithkline, LLC. | $30.92 | 2021-2022 | |
| Csl Behring | $24.46 | 2020 | |
| Exact Sciences Corporation | $24.26 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $19.51 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.44 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $17.91 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $16.31 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.53 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.29 | 2022 | |
| Horizon Therapeutics Plc | $13.80 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Malkus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.